



Final Appraisal Recommendation

Advice No: 1715 – June 2015

Avanafil (Spedra[®]▼) 50 mg, 100 mg and 200 mg tablets

Submission by A. Menarini Farmaceutica Internazionale SRL

Recommendation of AWMSG

Avanafil (Spedra[®]▼) is recommended as an option for use within NHS Wales for the treatment of erectile dysfunction in adult men.

Additional note(s):

- Please refer to the Summary of Product Characteristics for the full licensed indication.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1261), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue	A. Menarini Farmaceutica Internazionale SRL
Date of first issue	June 2015
Last reviewed	June 2018

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 1715:
Avanafil (Spedra[®]▼) 50 mg, 100 mg and 200 mg tablets. June 2015.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at www.evidence.nhs.uk.

For full details on our accreditation visit: www.nice.org.uk/accreditation.